GSK (GSK) DIvidends Date & History

Key Takeaways

• GSK pays a quarterly dividend with a current yield of roughly 3.5%, based on about $1.79 per American Depositary Receipt (ADR) over the trailing 12 months.
• The payout ratio sits in the mid-40s to mid-50s percent of earnings, a level generally viewed as manageable and sustainable.
• GSK rebased its dividend downward after spinning off its consumer-health business, Haleon, in July 2022, and has since resumed annual increases.
• The dividend has grown in three consecutive years, signaling a cautious return to a growth-oriented payout policy.
• With a yield above the broader pharmaceutical sector average, GSK appeals primarily to income-focused and long-term dividend investors.

Dividend Overview

GSK plc, formerly GlaxoSmithKline, is a United Kingdom-based global biopharmaceutical company whose shares trade on the New York Stock Exchange as an ADR (American Depositary Receipt). The company pays its dividend quarterly, distributing approximately $1.79 per ADR over the trailing 12 months, which translates to a dividend yield of about 3.5%.

GSK is best characterized as a hybrid of an income stock and a recovering dividend growth stock. Its yield is meaningfully higher than that of many large-cap growth-oriented peers, making it attractive to investors seeking current income. At the same time, the payout was deliberately reduced following the 2022 separation of its consumer-healthcare division, so the company is still rebuilding its reputation as a consistent dividend grower rather than a high-yield or aggressive-growth payer.

Dividend History and Growth

GSK has a long record of returning cash to shareholders, with dividend payments stretching back decades. However, the payout trajectory has not been a straight line. When the company demerged its consumer-health business into Haleon in July 2022, management reset the ordinary dividend to reflect the smaller, more focused pharmaceutical and vaccines operation. On a share-consolidation-adjusted basis, the total dividend for 2022 was 61.25 pence per share, a meaningful step down from prior levels.

Since that rebasing, GSK has cautiously rebuilt its payout. The company has increased its dividend in three consecutive years, and recent year-over-year growth has tracked in the mid-single-digit range. While the five-year dividend growth rate remains negative because of the 2022 reset, the recent trend suggests a deliberate return to steady, modest annual increases aligned with earnings and free cash flow growth.

Dividend Sustainability and Payout Ratio

GSK's dividend appears reasonably well covered by earnings and cash flow. The earnings payout ratio is commonly reported in the mid-40s to mid-50s percent, depending on the measurement period, while the cash-flow payout ratio is broadly similar. Ratios in this range leave a comfortable buffer to fund the pipeline, research and development, and debt obligations while still rewarding shareholders.

Free cash flow coverage is a particularly important metric for pharmaceutical companies, whose earnings can be volatile around patent expirations and product launches. GSK's dividend is supported by a diversified portfolio spanning specialty medicines, vaccines, and HIV treatments, which helps smooth revenue. As with any leveraged healthcare company, debt levels and litigation costs remain factors to monitor, but the current payout does not appear stretched relative to the company's earnings and cash generation.

Dividend Compared to Industry Peers

Within the large-cap pharmaceutical group, GSK's roughly 3.5% yield is competitive. It generally exceeds the yields of peers such as MRK (Merck), JNJ (Johnson & Johnson), and AZN (AstraZeneca), while sitting below the higher-yielding names like PFE (Pfizer). This places GSK in the upper-middle tier of the sector on an income basis.

What distinguishes GSK is its combination of an above-average yield and a conservative payout ratio, giving it room to grow the dividend faster than some higher-yielding peers that pay out a larger share of earnings. For investors comparing pharmaceutical income options, GSK offers a balanced profile of current income and modest growth potential.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener can help identify dividend stocks, income-focused investments, trending stocks, and breakout candidates more efficiently than manual screening. To explore opportunities like GSK and comparable dividend payers, visit the AI Screener today.

Is This Stock Attractive for Dividend Investors?

GSK is likely to appeal most to income-oriented and long-term dividend investors who prioritize a dependable, above-average yield over rapid payout growth. The roughly 3.5% yield, combined with a manageable payout ratio and the backing of a diversified pharmaceutical and vaccines business, offers a relatively stable income stream. Conservative investors seeking established, cash-generative healthcare exposure may also find the profile suitable.

Dividend growth investors should note that GSK's recent increases have been modest, and its multi-year growth rate remains negative because of the 2022 rebasing. Investors requiring an unbroken long-term dividend growth streak may find GSK less aligned with their criteria. Overall, the stock presents a balanced trade-off: meaningful current income with cautious, rebuilding growth, rather than the aggressive payout expansion found at some peers. As always, suitability depends on individual objectives and risk tolerance.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations